Boehringer Ingelheim Puts 190-acre Pharma Campus on Market

PETERSBURG, VA-Germany-based Boehringer Ingelheim is putting its 190-acre multi-purpose pharmaceutical production campus up for sale and has tapped Jones Lang LaSalle to market the facility. Located at 2820 N. Normandy Dr. in this Richmond submarket, the campus has the potential for multiple uses in related industries, Stan Manoogian, SVP in JLL's Richmond office tells GlobeSt.com.

"It is a world-class, state-of-the-art production facility for the manufacture of Active Pharmaceutical Ingredients (APIs) for human, veterinary and clinical research use. It could be adapted for pharmaceutical users, specialty chemical manufacturers and manufacturers of nutriceuticals among other uses," he says.

Another possibility is higher education. Manoogian says JLL has reached out to the engineering school of a large university in Virginia to see if they might be interested in acquiring a portion for research activities. "We think it is likely the campus will be subdvided for multiple uses," he adds.

JLL is not quoting pricing at this moment.

Boehringer Ingelheim has upgraded the facility since its development in 1977, including a significant expansion in 2009. The campus meets DEA regulations for on-site production of Class II substances.

The campus also features a pilot plant scale for development and a Kilo lab. There is integrated utility, production, wastewater and emission control infrastructure, and four synthesis buildings that support multi-product manufacturing.